These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

566 related articles for article (PubMed ID: 27859259)

  • 1. Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.
    Bridgeman VL; Vermeulen PB; Foo S; Bilecz A; Daley F; Kostaras E; Nathan MR; Wan E; Frentzas S; Schweiger T; Hegedus B; Hoetzenecker K; Renyi-Vamos F; Kuczynski EA; Vasudev NS; Larkin J; Gore M; Dvorak HF; Paku S; Kerbel RS; Dome B; Reynolds AR
    J Pathol; 2017 Feb; 241(3):362-374. PubMed ID: 27859259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vessel co-option and resistance to anti-angiogenic therapy.
    Kuczynski EA; Reynolds AR
    Angiogenesis; 2020 Feb; 23(1):55-74. PubMed ID: 31865479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of tumour vascularization in experimental lung metastases.
    Szabo V; Bugyik E; Dezso K; Ecker N; Nagy P; Timar J; Tovari J; Laszlo V; Bridgeman VL; Wan E; Frentzas S; Vermeulen PB; Reynolds AR; Dome B; Paku S
    J Pathol; 2015 Feb; 235(3):384-96. PubMed ID: 25319725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases.
    Frentzas S; Simoneau E; Bridgeman VL; Vermeulen PB; Foo S; Kostaras E; Nathan M; Wotherspoon A; Gao ZH; Shi Y; Van den Eynden G; Daley F; Peckitt C; Tan X; Salman A; Lazaris A; Gazinska P; Berg TJ; Eltahir Z; Ritsma L; Van Rheenen J; Khashper A; Brown G; Nystrom H; Sund M; Van Laere S; Loyer E; Dirix L; Cunningham D; Metrakos P; Reynolds AR
    Nat Med; 2016 Nov; 22(11):1294-1302. PubMed ID: 27748747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different Forms of Tumor Vascularization and Their Clinical Implications Focusing on Vessel Co-option in Colorectal Cancer Liver Metastases.
    Haas G; Fan S; Ghadimi M; De Oliveira T; Conradi LC
    Front Cell Dev Biol; 2021; 9():612774. PubMed ID: 33912554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Mechanism of tumour vascularisation in experimental lung metastases].
    Szabó V
    Magy Onkol; 2020 Mar; 64(1):73-75. PubMed ID: 32181766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches?
    Coelho AL; Gomes MP; Catarino RJ; Rolfo C; Lopes AM; Medeiros RM; Araújo AM
    Oncotarget; 2017 Jun; 8(24):39795-39804. PubMed ID: 26950275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathological features of vessel co-option versus sprouting angiogenesis.
    Latacz E; Caspani E; Barnhill R; Lugassy C; Verhoef C; Grünhagen D; Van Laere S; Fernández Moro C; Gerling M; Dirix M; Dirix LY; Vermeulen PB
    Angiogenesis; 2020 Feb; 23(1):43-54. PubMed ID: 31655928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?
    Donnem T; Hu J; Ferguson M; Adighibe O; Snell C; Harris AL; Gatter KC; Pezzella F
    Cancer Med; 2013 Aug; 2(4):427-36. PubMed ID: 24156015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutrophils expressing lysyl oxidase-like 4 protein are present in colorectal cancer liver metastases resistant to anti-angiogenic therapy.
    Palmieri V; Lazaris A; Mayer TZ; Petrillo SK; Alamri H; Rada M; Jarrouj G; Park WY; Gao ZH; McDonald PP; Metrakos P
    J Pathol; 2020 Jun; 251(2):213-223. PubMed ID: 32297656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor microenvironment conditions that favor vessel co-option in colorectal cancer liver metastases: A theoretical model.
    Rada M; Lazaris A; Kapelanski-Lamoureux A; Mayer TZ; Metrakos P
    Semin Cancer Biol; 2021 Jun; 71():52-64. PubMed ID: 32920126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apelin inhibition prevents resistance and metastasis associated with anti-angiogenic therapy.
    Uribesalgo I; Hoffmann D; Zhang Y; Kavirayani A; Lazovic J; Berta J; Novatchkova M; Pai TP; Wimmer RA; László V; Schramek D; Karim R; Tortola L; Deswal S; Haas L; Zuber J; Szűcs M; Kuba K; Dome B; Cao Y; Haubner BJ; Penninger JM
    EMBO Mol Med; 2019 Aug; 11(8):e9266. PubMed ID: 31267692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular differences of angiogenic versus vessel co-opting colorectal cancer liver metastases at single-cell resolution.
    Fleischer JR; Schmitt AM; Haas G; Xu X; Zeisberg EM; Bohnenberger H; Küffer S; Teuwen LA; Karras PJ; Beißbarth T; Bleckmann A; Planque M; Fendt SM; Vermeulen P; Ghadimi M; Kalucka J; De Oliveira T; Conradi LC
    Mol Cancer; 2023 Jan; 22(1):17. PubMed ID: 36691028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of vessel co-option lung metastases mouse models for single-cell isolation of metastases-derived cells and endothelial cells.
    Cuypers A; Teuwen LA; Bridgeman VL; de Rooij LPMH; Eelen G; Dewerchin M; Cantelmo AR; Kalucka J; Bouché A; Vinckier S; Carton A; Manderveld A; Vermeulen PB; Reynolds AR; Carmeliet P
    STAR Protoc; 2022 Dec; 3(4):101691. PubMed ID: 36173713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy.
    Vasudev NS; Goh V; Juttla JK; Thompson VL; Larkin JM; Gore M; Nathan PD; Reynolds AR
    Br J Cancer; 2013 Sep; 109(5):1230-42. PubMed ID: 23922108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vessel co-option in cancer.
    Kuczynski EA; Vermeulen PB; Pezzella F; Kerbel RS; Reynolds AR
    Nat Rev Clin Oncol; 2019 Aug; 16(8):469-493. PubMed ID: 30816337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models.
    Singh M; Couto SS; Forrest WF; Lima A; Cheng JH; Molina R; Long JE; Hamilton P; McNutt A; Kasman I; Nannini MA; Reslan HB; Cao TC; Ho CC; Barck KH; Carano RA; Foreman O; Eastham-Anderson J; Jubb AM; Ferrara N; Johnson L
    J Pathol; 2012 Aug; 227(4):417-30. PubMed ID: 22611036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis.
    Shojaei F; Simmons BH; Lee JH; Lappin PB; Christensen JG
    Cancer Lett; 2012 Jul; 320(1):48-55. PubMed ID: 22269210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiogenesis of gastrointestinal tumours and their metastases--a target for intervention?
    Garcea G; Lloyd TD; Gescher A; Dennison AR; Steward WP; Berry DP
    Eur J Cancer; 2004 Jun; 40(9):1302-13. PubMed ID: 15177488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases.
    Jeong HS; Jones D; Liao S; Wattson DA; Cui CH; Duda DG; Willett CG; Jain RK; Padera TP
    J Natl Cancer Inst; 2015 Sep; 107(9):. PubMed ID: 26063793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.